In particular, through methods such as high-throughput screening, many studies have identified RGS17 as a new target in lung and prostate cancers, and the specific mechanism may be related to the induction of tumour cell proliferation by RGS17 through regulation of the cAMP-PKA-CREB pathway [13–16]. Here, RGS17 is linked to prostate carcinoma.